Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

OBJECTIVE: To conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab. DESIGN: A Markov model with a lifetime horizon and monthly cycles was developed based on the York model. Four health states were included: a b...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweikert, Bernd, Malmberg, Chiara, Núñez, Mercedes, Dilla, Tatiana, Sapin, Christophe, Hartz, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430486/
https://www.ncbi.nlm.nih.gov/pubmed/32792421
http://dx.doi.org/10.1136/bmjopen-2019-032552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430486/
https://www.ncbi.nlm.nih.gov/pubmed/32792421
http://dx.doi.org/10.1136/bmjopen-2019-032552

Ejemplares similares